{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T15:51:23Z","timestamp":1789314683239,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T00:00:00Z","timestamp":1297123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1038\/nrurol.2010.234","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T13:12:39Z","timestamp":1297170759000},"page":"165-171","source":"Crossref","is-referenced-by-count":45,"title":["Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC"],"prefix":"10.1038","volume":"8","author":[{"given":"Toshinari","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tram Anh T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan K.","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh V.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderich E.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph J.","family":"DeBerardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"BFnrurol2010234_CR1","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271\u20132281 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2010234_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449\u2013456 (2008).","journal-title":"Lancet"},{"key":"BFnrurol2010234_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406\u2013410 (2002).","journal-title":"Nat. Genet."},{"key":"BFnrurol2010234_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/376435","volume":"73","author":"JR Toro","year":"2003","unstructured":"Toro, J. R. et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95\u2013106 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol2010234_CR5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1737","volume":"5","author":"E Gottlieb","year":"2005","unstructured":"Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857\u2013866 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrurol2010234_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/jmg.2005.036400","volume":"43","author":"HJ Lehtonen","year":"2006","unstructured":"Lehtonen, H. J. et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 43, 523\u2013526 (2006).","journal-title":"J. Med. Genet."},{"key":"BFnrurol2010234_CR7","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","volume":"177","author":"RL Grubb 3rd","year":"2007","unstructured":"Grubb, R. L. 3rd et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol. 177, 2074\u20132079 (2007).","journal-title":"J. Urol."},{"key":"BFnrurol2010234_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2350-9-20","volume":"9","author":"JP Bayley","year":"2008","unstructured":"Bayley, J. P., Launonen, V. & Tomlinson, I. P. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med. Genet. 9, 20 (2008).","journal-title":"BMC Med. Genet."},{"key":"BFnrurol2010234_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nsb0895-654","volume":"2","author":"TM Weaver","year":"1995","unstructured":"Weaver, T. M., Levitt, D. G., Donnelly, M. I., Stevens, P. P. & Banaszak, L. J. The multisubunit active site of fumarase C from Escherichia coli. Nat. Struct. Biol. 2, 654\u2013662 (1995).","journal-title":"Nat. Struct. Biol."},{"key":"BFnrurol2010234_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143\u2013153 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrurol2010234_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cancergencyto.2009.08.018","volume":"196","author":"Y Yang","year":"2010","unstructured":"Yang, Y. et al. UOK 262 cell line, fumarate hydratase deficient (FH\u2212\/FH\u2212) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet. Cytogenet. 196, 45\u201355 (2010).","journal-title":"Cancer Genet. Cytogenet."},{"key":"BFnrurol2010234_CR12","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1093\/hmg\/ddq305","volume":"19","author":"L O'Flaherty","year":"2010","unstructured":"O'Flaherty, L. et al. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet. 19, 3844\u20133851 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrurol2010234_CR13","first-page":"4554","volume":"62","author":"M Kiuru","year":"2002","unstructured":"Kiuru, M. et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 62, 4554\u20134557 (2002).","journal-title":"Cancer Res."},{"key":"BFnrurol2010234_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jcp.2003.011767","volume":"57","author":"MR Morris","year":"2004","unstructured":"Morris, M. R. et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J. Clin. Pathol. 57, 706\u2013711 (2004).","journal-title":"J. Clin. Pathol."},{"key":"BFnrurol2010234_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ncpuro0711","volume":"4","author":"S Sudarshan","year":"2007","unstructured":"Sudarshan, S., Pinto, P. A., Neckers, L. & Linehan, W. M. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer\u2014a distinct form of hereditary kidney cancer. Nat. Clin. Pract. Urol. 4, 104\u2013110 (2007).","journal-title":"Nat. Clin. Pract. Urol."},{"key":"BFnrurol2010234_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","volume":"26","author":"TK Choueiri","year":"2008","unstructured":"Choueiri, T. K. et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26, 127\u2013131 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2010234_CR17","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1200\/jco.2010.28.15_suppl.4604","volume":"28","author":"ER Plimack","year":"2010","unstructured":"Plimack, E. R. et al. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study. J. Clin. Oncol. 28, 4604 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2010234_CR18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","volume":"14","author":"PJ Pollard","year":"2005","unstructured":"Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1\u03b1 in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231\u20132239 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrurol2010234_CR19","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1128\/MCB.00483-09","volume":"29","author":"S Sudarshan","year":"2009","unstructured":"Sudarshan, S. et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1\u03b1 stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell Biol. 29, 4080\u20134090 (2009).","journal-title":"Mol. Cell Biol."},{"key":"BFnrurol2010234_CR20","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633\u20134646 (2006).","journal-title":"Oncogene"},{"key":"BFnrurol2010234_CR21","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/pros.21172","volume":"70","author":"M Stein","year":"2010","unstructured":"Stein, M. et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70, 1388\u20131394 (2010).","journal-title":"Prostate"},{"key":"BFnrurol2010234_CR22","doi-asserted-by":"crossref","first-page":"14025","DOI":"10.1200\/jco.2007.25.18_suppl.14025","volume":"25","author":"LE Raez","year":"2007","unstructured":"Raez, L. E. et al. Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H\/N) carcinomas. J. Clin. Oncol. 25, 14025 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2010234_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/hmg\/ddg148","volume":"12","author":"NA Alam","year":"2003","unstructured":"Alam, N. A. et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12, 1241\u20131252 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrurol2010234_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2010234_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"BFnrurol2010234_CR26","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/cncr.24230","volume":"115","author":"WM Linehan","year":"2009","unstructured":"Linehan, W. M. et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115, 2252\u20132261 (2009).","journal-title":"Cancer"},{"key":"BFnrurol2010234_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"BFnrurol2010234_CR28","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1158\/1078-0432.CCR-07-0074","volume":"13","author":"DA Mankoff","year":"2007","unstructured":"Mankoff, D. A. et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin. Cancer Res. 13, 3460\u20133469 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2010234_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577\u2013590 (2003).","journal-title":"Cell"},{"key":"BFnrurol2010234_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1365-2443.2003.00615.x","volume":"8","author":"N Kimura","year":"2003","unstructured":"Kimura, N. et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8, 65\u201379 (2003).","journal-title":"Genes Cells"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.234","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:46:52Z","timestamp":1684471612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2010.234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BFnrurol2010234"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2010.234","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,8]]}}}